抗胆固醇负担与艾滋病毒感染者睡眠质量之间的关联
Maria Mazzitelli1, Mattia Trunfio2, Vincenzo Scaglione1
1Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
抗胆固醇负担 (ACB) 与艾滋病毒感染者的睡眠质量差有关. 通过药物审查减少ACB可以改善这一群体的睡眠和生活质量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 艾滋病毒 医学 艾滋病毒 医学
- 睡眠医学 睡眠医学
背景情况:
- 没有先前的研究检查过艾滋病毒感染者抗胆固醇负担 (ACB) 和睡眠质量 (SQ) 之间的联系.
- 抗胆固醇药物是常用的药物,可以引起影响睡眠的副作用.
研究的目的:
- 研究艾滋病毒感染者中ACB和SQ之间的关联.
- 评估这个人群中睡眠质量差和高ACB的流行程度.
主要方法:
- 一项涉及1200名艾滋病毒感染者的横截面研究.
- 用患者报告的结果来衡量SQ (PSQI,ISI,ESS) 和ACB (ACBS).
- 一般化的线性模型被用来分析关联,调整并发病和治疗.
主要成果:
- 16.8%的参与者服用抗胆固醇药物,较高的ACB得分与更差的睡眠指标有关.
- 临床相关的失眠,不良的SQ和显著的白天嗜睡是普遍存在的.
- 更高的ACB独立地与更差的ISI和PSQI分数相关,即使经过调整以考虑混因素.
结论:
- 艾滋病毒感染者的ACB和睡眠障碍之间存在复杂的关系.
- 临床医生应评估SQ并审查药物以减少ACB,从而可能改善生活质量.
- 建议停止处方高ACB药物,与EACS指南保持一致.
更多相关视频
05:34Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
Published on: August 18, 2023
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
相关概念视频
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Sleep Apnea
The condition is more prevalent among...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
